Tracks at MDA’s Upcoming 2026 Clinical & Scientific Conference: Barry J. Byrne, MD, PhD

WATCH TIME: 4 minutes

“I really think that this is where both the basic science and foundational science communities meet together with their clinical colleagues and brainstorm on ideas about what the next therapeutic strategies should be in the host of neuromuscular disorders that are covered by the MDA umbrella.”

This content was originally published by our sister publication, CGTLive.

The Muscular Dystrophy Association (MDA), which is dedicated to serving the community of patients with neuromuscular disorders, including muscular dystrophies and other types of neuromuscular disease, will be holding its annual MDA Clinical & Scientific Conference from March 8 to 11, 2026, in Orlando, Florida. As every year, it will aim to gather physicians, clinical trial investigators, academic researchers, patient advocates, biotech executives, and other stakeholders with the shared goal of disseminating and discussing the latest findings in neuromuscular disease research.

In the lead up to this year’s meeting, NeurologyLive®’s sister site CGTLive® reached out to Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida, to learn more about what attendees can expect at the 2026 event, especially regarding this year’s various tracks. He described the meeting as a key place for providers across the neuromuscular care spectrum to connect and learn about cutting edge therapies. The conference this year features dedicated tracks, including ones for neurologists and neuromuscular specialists, amyotrophic lateral sclerosis (ALS) care, allied health professionals, and drug development.

Byrne also highlighted the opening session, featuring Biotechnology Innovation Organization (BIO) CEO John Crowley, JD, MBA, who will speak about drug development and patient advocacy, particularly in rare neuromuscular diseases. Byrne additionally noted that he is personally looking forward to late breaking clinical trial results traditionally presented on the final day. He added that cell and gene therapy will be an important topic this year, including discussions on safety, risk mitigation, and next generation therapies now entering the clinic.

Registration for the 2026 MDA Conference is now open! The meeting is set to be held at Hilton Orlando, Orlando, Florida, from March 8 to 11, 2026. To register and for more information, head to www.mdaconference.org